|
|
|
|
|
Octreotide Acetate |
|
C49H66N10O10S2 |
|
83150-76-9 |
|
It is clinically mainly used to treat the following acromegalics, the gastroenteropancreatic endocrine tumors, the carcinoid accompanied with the features of carcinoid syndrome, the vasoactive intestinal peptide tumor, glucagonoma, gastrinoma/ Zollinger-Ellison Syndrome, insulinoma (be used for the prevention and maintenance of preoperation hypoglycemia) and growth hormone release factor adenoma. |
|
Parameters of Product: 1 .Appearance :White powder 2 .Specific Optical Rotation (c=0.5,95%HAc) :-45.0~-55.0¡Æ 3 .Water Content(Karl Fischer) :¡Â6.0% 4 .Acetate Content(by HPLC) :¡Â15.0% 5 .Amino Acid Composition :¡¾10% of theoretical 6 .Purity (by HPLC) :¡Ã98.0% 7 .Single Impurity(by HPLC) :¡Â1.0% 8 .Peptide Content(by N%) :¡Ã80% 9 .Assay(By Anhydrous, Acetic Acid-free ) :95.0~105.0% 10 .Bacterial Endotoxins :¡Â5EU/mg
|
Industrial field |
pharmaceutical |
|
|
|
|
|
|
|
There are no existing companies to distribute selected chemical product |
|
|
|
|
|